|
業務類別
|
Biotechnology |
|
業務概覽
|
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors. |
| 公司地址
| 401 East Jackson Street, Suite 3300, Tampa, FL, USA, 33602 |
| 電話號碼
| +1 929 274-7510 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.akaritx.com |
| 員工數量
| 6 |
| Mr. Kameel D. Farag |
Interim Chief Financial Officer and Principal Accounting Officer |
-- |
30/03/2026 |
| Mr. Abizer Gaslightwala |
Director, Chief Executive Officer and President |
-- |
30/03/2026 |
|
|
| Mr. Robert B. Bazemore, Jr |
Independent Director |
30/03/2026 |
| Mr. Sandip I. Patel |
Independent Director |
30/03/2026 |
| Mr. James R. Neal, M.B.A.,M.S. |
Independent Director |
30/03/2026 |
| Dr. Hoyoung Huh,M.D.,PhD |
Chairman of the Board |
30/03/2026 |
| Dr. Raymond Prudo-Chlebosz, M.D. |
Independent Director |
30/03/2026 |
| Dr. Samir R. Patel, M.D. |
Director |
30/03/2026 |
| Mr. Abizer Gaslightwala |
Director, Chief Executive Officer and President |
30/03/2026 |
|
|
|
|
